Related Experiment Video
Updated: Sep 29, 2025
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
The Precise Detection of HER-2 Expression in Breast Cancer Cell via Au25 Probes
Xu Han1,2, Zhesheng He1,2, Wenchao Niu3
1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
Abstract:
Triple-negative breast cancer (TNBC) accounts for nearly one-quarter of all breast cancer cases, but effective targeted therapies for this disease remain elusive because TNBC cells lack the expression of the most common three receptors seen in other subtypes of breast cancers. The medium-term diagnosis of breast cancers is essential for development and prognosis. According to reports, patients with TNBC may be converted to a positive epidermal growth factor receptor 2(HER-2) after chemotherapy, and trastuzumab treatment will have a better prognosis. Therefore, it is important to accurately quantify the expression of HER-2 in breast cancer cells. Herein, we design a red fluorescent Au25 probe synthesized with BSA-biotin as the ligand, which is accurately quantified by HER-2 primary antibody-biotin using the avidin system. The quantitative detection of the expression of HER-2 in breast cancers is helpful for the companion diagnostic of breast cancer treatment and provides follow-up treatment.
Insights
A novel red fluorescent probe accurately quantifies human epidermal growth factor receptor 2 (HER-2) expression in triple-negative breast cancer (TNBC). This method aids in identifying patients who may benefit from HER-2 targeted therapies after chemotherapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Triple-negative breast cancer (TNBC) lacks common therapeutic targets, necessitating novel diagnostic approaches.
- Accurate quantification of human epidermal growth factor receptor 2 (HER-2) is crucial as TNBC can acquire HER-2 expression post-chemotherapy.
- HER-2 targeted therapies, like trastuzumab, show improved prognosis in HER-2 positive cases.
Purpose of the Study:
- To develop a sensitive and accurate method for quantifying HER-2 expression in breast cancer cells.
- To create a red fluorescent probe for enhanced visualization and quantification of HER-2.
- To support companion diagnostics for personalized breast cancer treatment strategies.
Main Methods:
- Synthesis of a red fluorescent gold nanocluster (Au25) probe utilizing BSA-biotin as a ligand.
- Quantification of HER-2 expression via an avidin-based system employing HER-2 primary antibody-biotin.
- Utilizing fluorescence detection for precise measurement of HER-2 levels.
Main Results:
- Successfully synthesized a red fluorescent Au25 probe with BSA-biotin ligand.
- Demonstrated accurate quantification of HER-2 expression using the developed probe and avidin system.
- Validated the probe's utility in detecting HER-2 expression relevant to treatment decisions.
Conclusions:
- The developed red fluorescent Au25 probe enables precise HER-2 quantification in breast cancer.
- This quantitative detection is vital for companion diagnostics and guiding follow-up treatments for TNBC patients.
- The probe offers a promising tool for personalized medicine in breast cancer therapy.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
